Are all echinacea species the same for research purposes?

No — and this is one of the most common sources of confusion. Echinacea purpurea, E. angustifolia and E. pallida have meaningfully different constituent profiles, and results from a study using one species and one plant part (say, E. pallida root) cannot simply be applied to another preparation. Most consumer products don't make the species distinction clearly visible.

What does an AUST L number on an echinacea product actually mean in Australia?

It means the product is listed on the Australian Register of Therapeutic Goods (ARTG) and that the TGA has assessed it for safety and quality, and that any claims made comply with the permitted indications framework. It does not mean the TGA has independently evaluated the product for efficacy before it went to market. Listed medicines sit in a different category from registered (AUST R) medicines, which undergo a more rigorous pre-market evidence review.

Why is the clinical research on echinacea so hard to interpret?

Several reasons. Studies use different species, different plant parts, different extraction methods, and different standardisation approaches — making direct comparison difficult. The Cochrane review on echinacea and upper respiratory tract infections flagged high heterogeneity between preparations as a key limitation. Effect sizes in positive trials have generally been modest, and publication bias is a known issue in the herbal medicine literature.

Is echinacea safe for everyone?

It is generally considered well-tolerated in healthy adults at typical short-term doses. However, documented allergic reactions, including anaphylaxis, have occurred — particularly in people with existing sensitivities to other Asteraceae (daisy family) plants such as ragweed, daisies or chrysanthemums. People on immunosuppressive medications should speak with a prescriber before use. The TGA's adverse event database contains relevant safety reports.

What are alkylamides and why do researchers study them in echinacea?

Alkylamides are lipophilic compounds found at relatively high concentrations in E. purpurea and E. angustifolia roots. They are of research interest partly because laboratory studies have shown they can interact with cannabinoid receptor binding sites — particularly CB2 receptor pathways, which are expressed in immune-associated tissues. Whether the concentrations achievable from a standard oral echinacea preparation are sufficient to produce meaningful receptor-level effects in humans has not been clearly established.

Echinacea: Traditional Use, Constituents and Evidence

By Naomi Ellison · 26 May 2026 · 7 min read

My nan kept three clumps of purple coneflower along the back fence, nestled between the lemon verbena and a sprawling comfrey she swore by for everything. She didn't call it Echinacea purpurea. She called it "the cold plant" and made no further apology for the name. Watching her pinch the flower heads each autumn, I never imagined I'd eventually spend a good chunk of my adult reading life trying to figure out what the science actually says about it.

Honest answer: it's complicated. And I'd argue the popular conversation around echinacea collapses that complexity in ways that don't serve anyone well , either the sceptics who dismiss it wholesale or the enthusiasts who treat it as settled.

A brief history of echinacea in plant medicine

Echinacea species , primarily E. purpurea, E. angustifolia and E. pallida , are native to the North American plains. Several Indigenous nations, including the Lakota and Cheyenne peoples, had documented use of the roots and aerial parts well before European contact. Ethnobotanical records collected during the 19th century describe applications ranging from wound poultices to use for snakebite and toothache. The eclectics; a heterodox school of North American physicians who embraced botanical remedies through the 1800s and into the early 20th century, picked up echinacea enthusiastically, and it became one of the most prescribed "botanical drugs" of that era.

From North America, interest moved to Europe, particularly Germany, where E. purpurea aerial parts became the focus of substantial phytochemical and clinical investigation from the mid-20th century onward. Germany's Commission E, the body that evaluated botanical medicines for the German health authority, produced monographs on echinacea preparations as far back as 1989. That European research tradition is partly why echinacea still occupies an unusual space in phytomedicine: it has a longer formal research history than most botanicals, and yet the data remain genuinely contested.

Key phytochemical constituents

Three main chemical classes drive most of the research interest in echinacea preparations.

Alkylamides are found in highest concentrations in E. purpurea and E. angustifolia roots. They are lipophilic, meaning they cross biological membranes relatively easily. This is pharmacologically interesting because some alkylamides have been shown in laboratory studies to interact with cannabinoid receptor binding sites, specifically, research has looked at CB2 receptor pathways. Our CB2 receptor glossary entry has background on what that receptor class does; the short version is that CB2 is expressed heavily in immune-associated tissues. Whether the concentrations of alkylamides achievable from a standard oral preparation are sufficient to produce meaningful receptor interactions in humans remains an open question. In vitro binding affinity and real-world human pharmacodynamics are very different things.

Caffeic acid derivatives; particularly echinacoside (prominent in E. pallida root) and cichoric acid (prominent in E. purpurea aerial parts), are water-soluble polyphenols. These are frequently used as marker compounds in standardised extracts, which means the concentration on the label is pegged to a measured amount of one or both. That standardisation matters for research comparability; comparing a whole dried herb to a concentrated extract pegged to cichoric acid to an ethanolic root tincture is a bit like comparing apples to engine oil.

Polysaccharides, high-molecular-weight carbohydrate chains, including arabinogalactans; are a third area of investigation, primarily in E. purpurea. These are poorly absorbed orally as intact molecules, which raises questions about their contribution to any observed effects beyond the gut environment.

It's also worth noting that the bioavailability picture for echinacea constituents is genuinely complex. Alkylamides appear to be relatively bioavailable orally; polysaccharides much less so. Species, plant part (root vs aerial), and extraction method all alter the constituent profile meaningfully. This is one reason the research literature is so hard to synthesise, studies often use incomparable preparations.

What the research shows, and where it falls short

The bulk of clinical research on echinacea has looked at upper respiratory tract infections. The Cochrane Collaboration published a review examining multiple randomised controlled trials, and its conclusions were carefully hedged: some preparations showed a statistically significant effect on certain outcomes in some trials, but heterogeneity between preparations was so high that pooled conclusions were difficult to draw. Effect sizes, where present, were modest.

A 2015 meta-analysis published in Evidence-Based Complementary and Alternative Medicine (NCBI: PMC4528044) similarly concluded that echinacea preparations were associated with reduced incidence and duration in some trial arms, but flagged publication bias and preparation heterogeneity as significant limitations.

Mechanistic research; largely in vitro and animal model work, has examined alkylamide effects on cytokine signalling and macrophage activity. But I'd flag here, as I do with a lot of preclinical data: cell culture results and rodent models do not translate automatically to human effects. The gap between "this compound does something measurable in a petri dish" and "this herb reliably does X in a human" is enormous, and it's a gap that popular writing on botanicals routinely underplays.

There are also safety signals worth noting. Echinacea is generally considered well-tolerated in healthy adults at typical doses and short durations, but documented cases of allergic reactions exist, including anaphylaxis in individuals with atopic sensitivities, particularly those with existing allergies to other Asteraceae (daisy family) plants. The TGA's adverse event database has records relevant to this. People on immunosuppressive therapy are typically advised to discuss use with a prescriber, though formal contraindication evidence is sparse.

How echinacea sits under Australian regulations

In Australia, echinacea preparations are most commonly listed medicines; those with an "AUST L" number on the Australian Register of Therapeutic Goods (ARTG). Listed medicines can carry only low-level, permitted indications from the TGA's permitted indications list; they are not evaluated for efficacy before listing, only for safety, quality and that the claims made are permitted. Registered medicines (AUST R) undergo a more rigorous pre-market efficacy assessment, but most herbal products, including most echinacea products, sit in the Listed category.

This is worth understanding as a consumer or researcher: an "AUST L" number on a bottle signals TGA oversight of manufacturing and safety, and compliance with Good Manufacturing Practice (GMP) requirements, but it is not a stamp of proven clinical efficacy. That distinction gets blurred constantly in retail and media coverage.

There are no specific import controls on echinacea in Australia analogous to, say, the kava import restrictions under the Customs (Prohibited Imports) Regulations 1956 (which limit personal importation quantities of kava). Echinacea products are freely available as listed complementary medicines. That said, any product carrying claims beyond the TGA's permitted indications list would be in breach of the Therapeutic Goods Act 1989 regardless of how many jars are stacked near the pharmacist's counter.

One thing I find genuinely underappreciated: the permitted indications framework means that Australian echinacea products are technically not allowed to say things that many overseas products print quite freely. The TGA's Permitted Indications database is publicly searchable, and it's educational to look at what's permitted versus what you'll sometimes see on imported products sold through online marketplaces. That gap is a regulatory problem that hasn't gone away.

Species, preparation and the standardisation problem

If there's one thing I'd want anyone reading about echinacea research to carry away, it's this: the three main species are not interchangeable, and neither are roots, aerial parts, or the various extraction methods used commercially. A tincture of E. angustifolia root has a very different constituent profile from a pressed juice of fresh E. purpurea aerial parts. Studies using one are not evidence for or against the other.

The concept of a standardised extract was partly developed to address this problem, pinning a preparation to a defined concentration of one or more marker compounds gives researchers and consumers a more reproducible reference point. But even standardisation has limits: a product standardised to 4% echinacoside might have wildly variable levels of alkylamides depending on which species and plant part were used, and the marker compound isn't necessarily the pharmacologically active one.

This is, honestly, one of the harder methodological challenges in phytomedicine research generally. It comes up with cannabis preparations too; the distinction between a full-spectrum extract and an isolate reflects the same underlying problem of defining what "the preparation" actually is when a plant contains dozens of potentially bioactive compounds.

Between bee inspections last spring I went back through a stack of older German Commission E materials at the Barr Smith Library in Adelaide. What struck me wasn't the conclusions, it was how carefully the monographs specified which plant part and which preparation type each statement applied to. That specificity is still missing from a lot of the public conversation about echinacea, decades later.

Sources

, Naomi Ellison, Botanical & phytomedicine writer

Common questions

Are all echinacea species the same for research purposes?: No — and this is one of the most common sources of confusion. Echinacea purpurea, E. angustifolia and E. pallida have meaningfully different constituent profiles, and results from a study using one species and one plant part (say, E. pallida root) cannot simply be applied to another preparation. Most consumer products don't make the species distinction clearly visible.
What does an AUST L number on an echinacea product actually mean in Australia?: It means the product is listed on the Australian Register of Therapeutic Goods (ARTG) and that the TGA has assessed it for safety and quality, and that any claims made comply with the permitted indications framework. It does not mean the TGA has independently evaluated the product for efficacy before it went to market. Listed medicines sit in a different category from registered (AUST R) medicines, which undergo a more rigorous pre-market evidence review.
Why is the clinical research on echinacea so hard to interpret?: Several reasons. Studies use different species, different plant parts, different extraction methods, and different standardisation approaches — making direct comparison difficult. The Cochrane review on echinacea and upper respiratory tract infections flagged high heterogeneity between preparations as a key limitation. Effect sizes in positive trials have generally been modest, and publication bias is a known issue in the herbal medicine literature.
Is echinacea safe for everyone?: It is generally considered well-tolerated in healthy adults at typical short-term doses. However, documented allergic reactions, including anaphylaxis, have occurred — particularly in people with existing sensitivities to other Asteraceae (daisy family) plants such as ragweed, daisies or chrysanthemums. People on immunosuppressive medications should speak with a prescriber before use. The TGA's adverse event database contains relevant safety reports.
What are alkylamides and why do researchers study them in echinacea?: Alkylamides are lipophilic compounds found at relatively high concentrations in E. purpurea and E. angustifolia roots. They are of research interest partly because laboratory studies have shown they can interact with cannabinoid receptor binding sites — particularly CB2 receptor pathways, which are expressed in immune-associated tissues. Whether the concentrations achievable from a standard oral echinacea preparation are sufficient to produce meaningful receptor-level effects in humans has not been clearly established.